Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluocortin is a synthetic corticosteroid drug primarily used in the form of its ester, fluocortin butyl. It acts as an anti-inflammatory and immunosuppressive agent. Fluocortin butyl is available in Germany for nasal application to treat perennial rhinitis and in Italy (as Vaspit) for topical treatment of skin diseases such as dermatitis, eczema, erythema, first-degree burns, and insect bites. Its mechanism involves induction of lipocortin 1 expression, which inhibits phospholipase A2—thereby reducing the synthesis of inflammatory mediators like prostaglandins and prostacyclins[6][8]. Clinical studies have shown it to be effective and well-tolerated when applied topically with minimal systemic corticosteroid activity[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluocortin.